News

The issued patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents. The phosphatidylinositol 3-kinase (PI3K)

AstraZeneca said that the court held the ‘314 patent to be non-obvious and properly reissued and it also found that no inequitable conduct was committed by any Shionogi

Mocon said that units in the Model 3/33 series are expected to offer automatic relative humidity (RH) capability through a new software interface which is helpful to the

Dr Schnipper brings with him 20 years of experience in the clinical development of medicines for the pharmaceutical and biotechnology industries. He also took up responsibility for many

GW Pharma and Otsuka signed the agreement in July 2007 with a three year term, and the collaboration is now extended upto the end of June 2013. As

TG 101348, an oral agent, is a potent inhibitor of Janus kinase 2 (JAK-2), developed for the treatment of patients with myeloproliferative diseases including myelofibrosis (MF). TargeGen said

Teva Pharmaceutical Industries currently has Rx approval for these products, and Teva and Sanofi-Aventis have settled their Paragraph IV/Hatch-Waxman litigation. Allegra 180mg, 60mg, and Allegra D-12 are indicated

On June 1, 2010, AMAG had submitted MAA for Feraheme for the treatment of iron deficiency anemia (IDA) in chronic kidney disease patients. AMAG has two partners for

The new laboratory is expected to deliver site support services to clinical investigators throughout China and offers overall benefits including shorter shipping distances between clinical sites and existing